I am an Associate Professor in the Division of Hematology and Medical Oncology in the NYU Perlmutter Cancer Center (PCC) at NYU Langone Health, the Clinical Director of Lymphoma and the Translational Director of Hematology. My scientific research focuses on the relationship between systemic immunity, tumor microenvironment, and lymphoid malignancies. I lead a multi-center investigation into the role of the microbiome in aggressive lymphoma and and the development of novel CAR T targest, and collaborate in team science with basic scientists in the development of novel immune based therapies, and biomarkers of lymphoma response. I have been among the pioneers of integration of checkpoint inhibitor therapy into the management of relapsed Hodgkin lymphoma (HL) developing and leading a national ETCTN supported clinical trial in this space. I have also played a key role in the development of novel immune related biomarkers in HL, and serve on national committees leading efforts to improve the next generation of HL therapies. I have contributed to the development of antibody drug conjugates (ADC) and bispecific antibodies in DLBCL and FL , and led national and international studies for relapsed FL and DLBCL. I have successfully obtained external peer-reviewed funding for my translational research from: the Lymphoma Research Foundation, the American Cancer Society, the Leukemia Lymphoma Foundation (LLS) and the National Cancer institute (NCI).